CHRISTOPHER M. STARR - 30 Jun 2023 Form 4 Insider Report for Monopar Therapeutics (MNPR)

Role: Director
Signature: /s/ Kim R. Tsuchimoto, Attorney-in-fact
Issuer symbol: MNPR
Transactions as of: 30 Jun 2023
Net transactions value: $0
Form type: 4
Filing time: 03 Jul 2023, 18:46:41 UTC
Previous filing: 04 Apr 2023
Next filing: 03 Oct 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MNPR	Common Stock	Options Exercise		+2,534	+14%		20,797	30 Jun 2023	Direct	F1
holding	MNPR	Common Stock						49,400	30 Jun 2023	See Footnote	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MNPR	Restricted Stock Units	Options Exercise	$0	-2,534	-33%	$0.000000	5,066	30 Jun 2023	Common Stock	2,534		Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares acquired on vesting and settlement of restricted stock units.
F2	49,400 shares of common stock held by the Christopher M. Starr and Sheri L. Starr Revocable Trust over which Dr. Starr serves as Trustee.
F3	On February 1, 2023, the reporting person was granted 10,133 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2023, June 30, 2023, September 30, 2023, and December 31, 2023. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.